At the 59th European Association for the Study of Diabetes in Germany, an expert panel discussed the tremendous ...
The human heart is a remarkable organ, tirelessly pumping blood to nourish every cell in our bodies. However, the burden it ...
More people than ever have an abnormal heart rhythm, or what doctors call atrial fibrillation (AFib). While family history and getting older can play a part, you can control something that can ...
Weight-loss stocks surged Tuesday after a landmark study showed that the popular obesity drug Wegovy not only helps you lose weight but could also potentially reduce the risk of heart attack or ...
A weight-loss drug has been proven to also reduce the risk of a stroke or heart attack, according to a new trial. The makers of Wegovy, Novo Nordisk, say its latest study shows it cuts risk of a ...
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.
Semaglutide, the active ingredient in drugs like Wegovy and Ozempic, is also effective at reducing symptoms of heart failure, new research shows. A study published this month in the New England ...
FEAR WEIGHT LOSS no longer. The science is in, and it doesn't take a crash diet, a juice cleanse, or anything else dramatic in order to lose weight. It's all about small changes in daily habit.
The products featured in this article have been independently reviewed. When you buy something through the retail links on this page, we may earn commission at no cost to you, the reader.
In the largest study of its kind, researchers found that including almonds in an energy restricted diet not only helped people to lose weight, but also improved their cardiometabolic health.
What is the DASH Diet? Dietary Approaches to Stop Hypertension, or DASH, is a diet plan recommended for those who want to prevent or stop high blood pressure. It does this by increasing the intake ...
The makers of Wegovy, Novo Nordisk, say its latest study shows it cuts risk of a cardiovascular event in overweight people with heart disease by a fifth. The firm hailed it a "landmark trial ...
